Allogeneic T cell immunomodulation after CD8+ depletion

This entry does not describe a specific, canonical molecular target, but rather a therapeutic approach using allogeneic leukocyte (T cell)-based immunomodulation. In this approach, CD8+ T cells (cytotoxic, potentially suppressive) are removed from the donor cell product to eliminate cytotoxic and suppressive activity, while activated CD4+ T cells are preserved and infused to provide immune "help" (e.g., cytokine secretion, licensing of antigen-presenting cells, promotion of other immune effector functions). The strategy is used to modulate the alloreactive immune response in hosts (e.g., in oncology or after transplantation) by providing helper T cell activity without the risks associated with CD8+ cytotoxic or suppressive T cell actions. This is not a molecular entity such as a receptor, enzyme, or channel; it is a therapeutic cell preparation and cannot be assigned a canonical abbreviation, family, or drug interaction profile as would be the case for a well-defined molecular drug target. In summary, the described "target" is not a standard molecular target but a cell-based immunomodulatory strategy, and it is too descriptive to be classified as a single molecule, receptor, or druggable target.

Other names

Allogeneic CD4+ T cell infusion (CD8+ depleted)CD8-depleted allogeneic leukocyte therapyAlloreactive CD4+ T cell immunomodulation

Immunomodulation by infusion of allogeneic CD4+ T cells after removal of cytotoxic/suppressive CD8+ cells, resulting in preserved helper T cell function (CD4+) and reduced cytotoxic T cell (CD8+) activity. Helper functions (cytokine secretion, dendritic cell licensing, support of host immune response) Lack of direct cytotoxic killing due to CD8+ T cell removal